** Shares of drug developer ARS Pharmaceuticals SPRY.O rise 2.6% to $11.15 premarket
** Co said late on Wednesday the U.S. FDA approved the expanded use of nasal spray for severe allergic reactions in patients who weigh between 15 kg and 30 kg
** The spray, sold under the brand name neffy, will be dosed at 1 mg for the new patient population
** Neffy is designed to be given at the first sign of a severe allergic reaction, and has been previously approved for people above 30 kg at dose of 2 mg
** SPRY has risen 21.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.